Aew Capital Management LP Has Increased Pennsylvania Real Estate Investment Trust (MAC) Holding By $6.90 Million; 6 Analysts Are Bullish Valeant Pharmaceuticals International, Inc. (VRX) Last Week

January 14, 2018 - By Maria Brooks

Aew Capital Management LP increased Pennsylvania Real Estate Investment Trust (MAC) stake by 22.02% reported in 2017Q3 SEC filing. Aew Capital Management LP acquired 689,600 shares as Pennsylvania Real Estate Investment Trust (MAC)’s stock declined 10.63%. The Aew Capital Management LP holds 3.82 million shares with $40.09M value, up from 3.13 million last quarter. Pennsylvania Real Estate Investment Trust now has $9.51B valuation. The stock decreased 0.21% or $0.13 during the last trading session, reaching $62.97. About 503,187 shares traded. Macerich Company (NYSE:MAC) has declined 18.62% since January 14, 2017 and is downtrending. It has underperformed by 35.32% the S&P500.

Among 27 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 6 have Buy rating, 5 Sell and 16 Hold. Therefore 22% are positive. Valeant Pharmaceuticals Intl had 148 analyst reports since July 21, 2015 according to SRatingsIntel. As per Monday, October 30, the company rating was maintained by BMO Capital Markets. The rating was initiated by Wells Fargo with “Underperform” on Friday, February 19. Piper Jaffray maintained the shares of VRX in report on Wednesday, August 9 with “Sell” rating. The firm earned “Equal-Weight” rating on Friday, October 2 by Morgan Stanley. The rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, August 22. On Friday, November 20 the stock rating was maintained by Mizuho with “Buy”. The firm earned “Hold” rating on Monday, November 6 by Canaccord Genuity. Stifel Nicolaus maintained the shares of VRX in report on Thursday, May 11 with “Buy” rating. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has “Buy” rating given on Monday, October 2 by Cantor Fitzgerald. The firm earned “Buy” rating on Friday, June 16 by Guggenheim. See Valeant Pharmaceuticals International, Inc. (NYSE:VRX) latest ratings:

15/12/2017 Broker: Mizuho Rating: Underperform Old Target: $7.00 New Target: $10.00 Maintain
14/12/2017 Broker: J.P. Morgan Rating: Sell Downgrade
14/12/2017 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade
04/12/2017 Broker: BTIG Research Rating: Hold Maintain
13/11/2017 Broker: Inc. Rating: Bmo Capital New Target: $16 17
09/11/2017 Broker: BTIG Research Rating: Hold Maintain
09/11/2017 Broker: H.C. Wainwright Rating: Hold New Target: $17.0 Maintain
07/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $23.0 Maintain
07/11/2017 Broker: Mizuho Rating: Sell New Target: $7.0 Maintain
06/11/2017 Broker: Canaccord Genuity Rating: Hold New Target: $16.0 Maintain

Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device firm worldwide. The company has market cap of $8.30 billion. It operates in three divisions: Bausch + Lomb/International, Branded Rx, and U.S. It has a 6.08 P/E ratio. Diversified Products.

The stock increased 0.13% or $0.03 during the last trading session, reaching $23.84. About 10.21 million shares traded. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has declined 48.51% since January 14, 2017 and is downtrending. It has underperformed by 65.21% the S&P500.

Investors sentiment decreased to 0.99 in 2017 Q3. Its down 0.09, from 1.08 in 2017Q2. It fall, as 43 investors sold Valeant Pharmaceuticals International, Inc. shares while 68 reduced holdings. 27 funds opened positions while 83 raised stakes. 169.87 million shares or 1.18% less from 171.89 million shares in 2017Q2 were reported. Alyeska Group Inc Ltd Partnership holds 1.87 million shares or 0.22% of its portfolio. Wells Fargo & Com Mn reported 166,145 shares. Walleye Trading Ltd invested in 0.05% or 743,922 shares. Paloma Prns Mngmt holds 0% or 19,926 shares. Credit Suisse Ag holds 0.01% or 1.02 million shares in its portfolio. Moreover, Wms Prns Ltd Liability has 0.02% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Invesco owns 1.43 million shares. Oppenheimer Incorporated invested in 0.01% or 28,925 shares. Ftb Advsrs Inc invested in 0% or 3,000 shares. 156,100 were accumulated by Intact Inv Management. Winslow Evans & Crocker Incorporated, a Massachusetts-based fund reported 4,000 shares. Commonwealth Equity Inc reported 48,007 shares. Carroll Financial Assocs has 0% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 3 shares. Shanda Asset Hldgs owns 700,000 shares. 152,400 were accumulated by Rbf Capital Ltd Liability Co.

Investors sentiment increased to 0.95 in Q3 2017. Its up 0.17, from 0.78 in 2017Q2. It improved, as 19 investors sold MAC shares while 114 reduced holdings. 39 funds opened positions while 87 raised stakes. 134.98 million shares or 0.62% more from 134.15 million shares in 2017Q2 were reported. 150 were reported by Exane Derivatives. Tudor Inv Corp Et Al accumulated 12,227 shares. The Connecticut-based Hartford Investment has invested 0.02% in Macerich Company (NYSE:MAC). Marathon Ptnrs Equity Mgmt Ltd Liability Corporation holds 6.89% or 285,000 shares. Vanguard holds 0.06% or 22.32 million shares in its portfolio. British Columbia Inv Corp reported 66,198 shares. Us Savings Bank De invested 0% in Macerich Company (NYSE:MAC). Bluecrest Management Limited has invested 0.03% in Macerich Company (NYSE:MAC). Korea Corp owns 40,400 shares. Quantitative Systematic Strategies stated it has 15,651 shares or 0.23% of all its holdings. Caisse De Depot Et Placement Du Quebec reported 27,969 shares stake. The Minnesota-based Thrivent Financial For Lutherans has invested 0.01% in Macerich Company (NYSE:MAC). The Japan-based Asset Mgmt One has invested 0.06% in Macerich Company (NYSE:MAC). Voya Inv Mgmt Ltd Limited Liability Company accumulated 66,743 shares. Ulysses Mngmt Limited Liability Company holds 2.18% in Macerich Company (NYSE:MAC) or 365,000 shares.

Among 21 analysts covering The Macerich Company (NYSE:MAC), 8 have Buy rating, 3 Sell and 10 Hold. Therefore 38% are positive. The Macerich Company had 48 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Macerich Company (NYSE:MAC) has “Buy” rating given on Tuesday, September 26 by J.P. Morgan. The firm earned “Hold” rating on Wednesday, August 31 by Jefferies. The firm earned “Neutral” rating on Tuesday, May 30 by Mizuho. The firm earned “Hold” rating on Monday, July 17 by Jefferies. Canaccord Genuity maintained it with “Hold” rating and $77 target in Monday, January 23 report. The stock of Macerich Company (NYSE:MAC) has “Hold” rating given on Monday, March 27 by Canaccord Genuity. The stock of Macerich Company (NYSE:MAC) earned “Hold” rating by Jefferies on Friday, June 16. The rating was downgraded by Bank of America on Monday, March 28 to “Neutral”. RBC Capital Markets maintained Macerich Company (NYSE:MAC) rating on Wednesday, August 9. RBC Capital Markets has “Buy” rating and $6600 target. Deutsche Bank maintained the stock with “Hold” rating in Monday, March 21 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts